Chemical Data :
Molecular Weight: 370.24
Molecular Formula: C21H30N4O2
ADB CHMINACA profile
ADB-CHMINACA is a member of the multitudinous class of indazole carboxamide synthetic cannabinoids. It also goes by the name MAB-CHMINACA.
It has the systematic and formal IUPAC name N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, empirical formula C21H30N4O2 and molar mass of 370.24 grams.
The name ADB-CHMINACA is formed from its longer name AminoDimethyloxoButaneCycloHexylMethylINdAzoleCarboxAmide.
It is supposed that ADB-CHMINACA is a potent agonist at the cannabanoid receptor CB1 owning to its structural similarity to similar synthetic cannabinoids and its reported effects; however this has not been proven experimentally. It is close in structure to MMB-CHMINACA. It is also structurally similar to AB-CHMINACA with a tert-butyl group in ADB CHMINACA instead of the isobutyl group in AB-CHMINACA.
The chemical is structurally similar to AB-CHMINACA by bearing an identical cyclohexyl group; however, the isobutyl moiety is substituted with a tert-butyl group.
ADB-CHMINACA may be of particular potency even in relation to this highly potent class of cannabinoids.
It is the full agonist action at CB1 and CB2 which sets these compounds apart from the effects of herbal cannabis. THC, the primary psychoactive chemical component of herbal marijuana, is a partial agonist at CB1 and has no risk of overdose. Unfortunately due to their full agonist effects not only do the synthetic cannabinoids have much stronger stoning effects but they can be toxic to health. Overdose, which can happen easily due to the tiny quantities involved, often results in hospitalisation with seizures and deaths reported. These compounds should therefore be approached with extra caution.
ADB-CHMINACA was banned by the state of Louisiana after being associated with more than 125 hospitalisations in the Baton Rouge area in October 2014.
The short term and long term effects of recreational use of ADB-CHMINACA on human health are not fully known. Its toxicological profile has not been established.
ADB-CHMINACA is not fit for human or animal consumption.
Unverifiable online reports do give use some indication of the subjective effects of this compound.
Users report effects lasting for a total of three hours with peak effects at 45 minutes.
Effects of the compound are said to be somewhat similar to cannabis. Online reports suggest ADB-CHMINACA acts to enhance emotions, immersion in the task at hand and to enhance music. It may induce states of paranoia and anxiety. Psychotic reactions are reported at high doses or with continual use.
ADB-CHMINACA is said to exert highly sedating effects on the body and is active at very minute doses in the single milligram range. Individuals who are intent on use must be aware that overdose can have fatal health consequences. Thus dosage measurements must be made with a milligram sensitive scale and volumetric titration.
The synthetic cannabinoids are known to be habit forming. Withdrawal effects have been reported from cessation after a period of continuous use.
Synthetic cannabinoids may potentiate the onset of mental health diseases such as schizophrenia especially in young adults and adolescents. They may cause a worsening of mental health conditions like depression and anxiety.
Properties Of ADB-CHMINACA
Other names and synonyms for ADBCHMINACA Crystal: